COVID-19 trials registries data warehouse

 Return to trial list

Trial - EUCTR2020-001656-18-NO


Column Value
Trial registration number EUCTR2020-001656-18-NO
Full text link
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

First author
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

Oslo University Hospital - Air Ambulance Department

Contact
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

cbuskop@ous-hf.no

Registration date
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

2020-04-24

Recruitment status
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

Recruiting

Study design
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

RCT

Allocation
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

Randomized

Design
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

Parallel

Masking
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

Blind label

Center
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

single-center

Study aim
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

Treatment

Inclusion criteria
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

All criteria must apply Patients ≥ 18 years of age at the time of inclusion and who are confirmed, suspected or probable cases of covid-19 based on WHO definitions and SpO2 <90% after 3 minutes 10 cm H2O PEEP + 100% O2 and who are treated by a physician who have specifically undergone formal training in pre-hospital INO administration and the present protocol.

Exclusion criteria
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

Only one criterion needs to apply for exclusion: 1. Patients who after 3 mins of ventilation with 10 cm H2O PEEP + 100% O2 i.e. at time of allocation (t0), have a SpO2 <50%, or a reliable SpO2 is impossible to obtain 2. Patients in severe kidney failure or dialysis, 3. Known or suspected pregnancy based on information on the time of inclusion. 4. Hypersensitivity to the active substance (NO) or to the excipient (N2) 5. Cardiac arrest 6. Patient in prison or custody by police 7. Staff present in treatment situation known to be pregnant 8. Any reason why, in the opinion of the treating physician, it is probably in the best interest of the patient not to participate in the trial. Female participants under the age of 50 years will be asked explicitly about possible pregnancy. If this cannot be obtained from the patient, next of kin will be asked if present. Information regarding exclusion criteria 2, 3 and 4 will be obtained from bystanders, often relatives or friends present at time of inclusion. If no clear information is available, the physicians shall include or exclude based on his/her best judgment at the time of inclusion.

Number of arms
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

2

Funding
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

Oslo University Hospital

Inclusion age min
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

18

Inclusion age max
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

100

Countries
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

Norway

Type of patients
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

Severe/critical disease at enrollment

Severity scale
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

7: Severe/critical disease at enrollment

Total sample size
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

54

primary outcome
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

The primary outcome measure is the change in SpO2, and the null hypothesis is that there is no difference in the change in SpO2 following initiation of INO

Notes
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

Declared number of arm (2.0) differs from found arms (1.0)

Phase
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

Phase 2

Arms
Last imported at : Nov. 5, 2021, 1:30 p.m.
Source : EU Clinical Trials Register

[{"arm_notes": "", "treatment_id": 890, "treatment_name": "Nitric oxide gas", "treatment_type": "Gas inhalation", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]